维普期刊资源整合服务平台（V6.5）

98篇 您的检索式：作者名="Kunitoh"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Concurrent daily carboplatin and accelerated hyperfractionnated thoracic radiotherapy in locally advanced non-small-cell lung cancer显示文摘	Kunitoh H Watanable K Nagatomo A	1997	Int J Radiat Oncol Biol Phys1997，37，：	1
2	Reasons for response differences seen in the V 15 32 INTEREST and IPASS trials显示文摘	Saijo N Takeuchi M Kunitoh H	2009	Nat Rey Clin Onco2009，6，5：	1
3	Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking independent manner in the Japanese 显示文摘	Shiraishi K Kohno T Kunitoh H Watanabe S Goto K Nishiwaki Y	2009	Carcinogenesis2009，30，1：	1
4	Randomized,open-label,multicenter phase II sutdy of bevacizumab in combination withcarboplatin and paclitaxel in chemotherapy-naive Japanese pa-tients with advanced or recurrent nonsquamous non-small celllung cancer(NSCLC):JO19907显示文摘	Nishio M Horai T Kunitoh H	2009	J Clin Oncol2009，2715，：	1
5	Randomized phase I] study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non- squamous non-small-cell lung cancer 显示文摘	Niho S Kunitoh H Nokihara H	2012	Lung Cancer2012，76，3：	1
6	Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae显示文摘	Okamoto H Nagatomo A Kunitoh H	1998	Cancer Chemother Pharmacol1998，42，4：	1
7	retrospective a- nalysis of safety and efficacy of low - dose docetaxel 60/m2 inadvanced non - small cell lung cacer patients previously treated with platinum -based chemotherapy 显示文摘	Nakamura Y Kunitoh H Kubota K	2007	Am J Clin Oncol2007，26，5：	1
8	Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials显示文摘	Sekine I Yamamoto N Kunitoh H	2004	Cancer Treatment Reviews2004，30，4：	1
9	Cancer chemotherapy in the elderly显示文摘	Sekine I Fukuda H Kunitoh H	1998	Jpn J Clin Oncol1998，28，8：	1
10	How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer显示文摘	Kunitoh H Suzuki K	2007	BrJ Cancer2007，96，10：	1
11	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials显示文摘	Saijo N Takeuchi M Kunitoh H	2009	Nat Rev Clin Oncol2009，6，5：	1
12	Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer 显示文摘	NIHO S KUNITOH H NOKIHARA H	2012	Lung Cancer2012，76，3：	1
13	Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients显示文摘	Kimie Sai Yoshiro Saito Hiromi Fukushima-Uesaka Koichi Kurose Nahoko Kaniwa Naoyuki Kamatani Kuniaki Shirao Noboru Yamamoto Tetsuya Hamaguchi Hideo Kunitoh Yuichiro Ohe Tomohide Tamura Yasuhide Yamada Hironobu Minami Atsushi Ohtsu Teruhiko Yoshida Nagahir	2008	Cancer Chemotherapy and Pharmacology2008，，3：	1
14	Phase I1 trail of docetaxelin previously untlated advanced non-small-cell lung cancer: a Japanese cooperative study显示文摘	Kunitoh H Watanabe K Onoshi T	1996	J Clin Oncol1996，14，5：	1
15	Figitumumab combined with carboplatin and paclitaxel in treatment-na?ve Japanese patients with advanced non-small cell lung cancer显示文摘	Yasushi Goto Ikuo Sekine Maki Tanioka Takashi Shibata Chiharu Tanai Hajime Asahina Hiroshi Nokihara Noboru Yamamoto Hideo Kunitoh Yuichiro Ohe Hironori Kikkawa Emiko Ohki Tomohide Tamura	2012	Investigational New Drugs2012，，4：	1
16	Immtmohistochemical KIT( CD117 ) expression in thymic epithelial tumors 显示文摘	Nakagawa K Matsuno Y Kunitoh H	2005	Chest2005，128，1：	1
17	Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese显示文摘	Shiraishi K Kohno T Kunitoh H	2009	Carcinogenesis2009，30，1：	1
18	Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group显示文摘	Kubota K Watanabe K Kunitoh H	2004	JClin Oncol2004，22，2：	1
19	Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae显示文摘	Okamoto H Nagatomo A Kunitoh H	1998	Cancer Chemother Pharmacol1998，42，4：	1
20	Reasons for response differ- ences seen in the V15-32, INTERSET and IPASS trials显示文摘	Saijo N Takeuchi M Kunitoh H	2009	Nat Rev Clin Oncol2009，6，5：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示